<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01214226</url>
  </required_header>
  <id_info>
    <org_study_id>2006-006944-78</org_study_id>
    <secondary_id>PROM 2006/0636</secondary_id>
    <secondary_id>2006-006944-78</secondary_id>
    <nct_id>NCT01214226</nct_id>
  </id_info>
  <brief_title>Double-blind Randomized Controlled Trial in Severe Alcoholic Hepatitis</brief_title>
  <acronym>CorpentoxHAA</acronym>
  <official_title>Evaluation of the Survival Benefit of the Adjunction of Pentoxifylline to Corticosteroids in Patients Suffering From Severe Alcoholic Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The treatment of severe forms of alcoholic hepatitis (AH) constitutes a major challenge for
      clinicians involved in the management of severe alcoholic liver disease. In patients with
      Maddrey function higher than 32, compelling evidence from data has shown that corticosteroids
      improve short-term survival. However, novel strategies or molecules are required in light of
      the fact that approximately 40 % of patients continue to die at 6 months. A double-blinded
      randomized controlled trial of 101 patients has showed that Pentoxifylline improves survival
      of patients with severe AH, as compared to placebo. In terms of mechanisms, the effect of
      pentoxifylline is related to prevention of hepatorenal function whereas corticosteroids
      induce an early improvement in liver function. When considering these differences of
      mechanisms, many clinicians suggest that the addition of pentoxyfilline to corticosteroids is
      an attractive option that needs to be tested in patients with severe AH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the present study is to determine whether or not the adjunction of Pentoxifylline
      to corticosteroids would improve 6-month survival of patients with severe alcoholic
      hepatitis. This multicenter, randomized, double-blinded, controlled, phase 3 trial was
      conducted in 24 centers located in France and Belgium. Alcoholic hepatitis was biopsy-proven.
      All eligible patients were randomly assigned in a 1:1 ratio to receive corticosteroids +
      Pentoxifylline or corticosteroids + Placebo. The primary outcome of the study was 6-month
      survival. Assuming a two-sided type I error of 0.05, a randomization ratio of 1:1 between the
      2 groups, 6-month survival of 64% in the Placebo and Corticosteroids group and of 78 % in the
      Pentoxifylline and Corticosteroids group, we estimated that with 268 randomized patients (134
      in each group), the study would have a power of 80% to detect this increase in 6-month
      survival in the Pentoxifylline and Corticosteroid group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatorenal syndrome</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of Lille model</measure>
    <time_frame>Seven days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Meld score (Model for End-stage Liver Disease) higher than 17</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">278</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <condition>Alcoholic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Pentoxifylline + Prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pentoxifylline 400 mg prolonged-released tablets 3 time a day [1200 mg/day]
+ Prednisolone 2 ORODISPERSIBLE TABLETS OF 20 MG 1 TIME PER DAY [40 mg/day]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Prednisolone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo prolonged-release tabled 3 time a day
+ Prednisolone 2 ORODISPERSIBLE TABLETS OF 20 MG 1 TIME PER DAY [40 mg/day]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline</intervention_name>
    <description>400 mg prolonged-released tablets 3 time per day for 1 month.</description>
    <arm_group_label>Placebo + Prednisolone</arm_group_label>
    <other_name>TORENTAL 400MG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>prolonged-release tablets 3 time per day for 1 month</description>
    <arm_group_label>Pentoxifylline + Prednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Alcohol consumption more than 40 gram/day for women and 50 gram/day for men

          -  Maddrey discriminant function higher than 32

          -  Onset of jaundice within the 3 previous months

          -  Biopsy-proven alcoholic hepatitis

        Exclusion Criteria:

          -  Hypersensitivity to pentoxifylline

          -  Any severe disease that may potential affect survival such as cardiac failure,
             ischemic cardiopathy, respiratory failure

          -  Any neoplasm that occurred within the 2 previous years

          -  Hepatocellular carcinoma or any previous diagnosis of hepatocellular carcinoma

          -  Portal thrombosis

          -  Severe gastrointestinal bleeding

          -  Uncontrolled sepsis within the 7 previous days

          -  Hepatorenal syndrome type I

          -  Viral and fungal infection

          -  Acute pancreatitis

          -  Any tuberculosis that occurred within the 5 previous years

          -  Psychiatric disorders that contraindicate the use of corticosteroids

          -  Infection related to virus of the hepatites B or C

          -  HIV infection (Human immunodeficiency virus)

          -  Any treatment with corticosteroids, immunosuppressive agents, budesonide, thalidomide
             or pentoxifylline that was given within the previous year

          -  Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe MATHURIN, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Brussel</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Verdier (AH-HP)</name>
      <address>
        <city>Bondy</city>
        <zip>93143</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier</name>
      <address>
        <city>Béthune</city>
        <zip>62408</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Antoine Béclère (Assistance Publique des Hôpiaux de Paris)</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon (AH-HP)</name>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Creil</city>
        <zip>60100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor (AP-HP)</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier</name>
      <address>
        <city>Dunkerque</city>
        <zip>59240</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Lens</city>
        <zip>62300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Sambre en avesnois</name>
      <address>
        <city>Maubeuge</city>
        <zip>59600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Nantes</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine (AP-HP)</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié-Salpétrière (AP-HP)</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin (AH-HP)</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Provo</name>
      <address>
        <city>Roubaix</city>
        <zip>59100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Strasbourg</city>
        <zip>67100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital, Nancy</name>
      <address>
        <city>Vandoeuvre les nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse (AH-HP)</name>
      <address>
        <city>Villejuif</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009 Jun 25;360(26):2758-69. doi: 10.1056/NEJMra0805786. Review.</citation>
    <PMID>19553649</PMID>
  </results_reference>
  <results_reference>
    <citation>Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, Canva-Delcambre V, Deltenre P, Mathurin P. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology. 2009 Aug;137(2):541-8. doi: 10.1053/j.gastro.2009.04.062. Epub 2009 May 13.</citation>
    <PMID>19445945</PMID>
  </results_reference>
  <results_reference>
    <citation>Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, Dharancy S, Texier F, Hollebecque A, Serfaty L, Boleslawski E, Deltenre P, Canva V, Pruvot FR, Mathurin P. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007 Jun;45(6):1348-54.</citation>
    <PMID>17518367</PMID>
  </results_reference>
  <results_reference>
    <citation>Mathurin P. Corticosteroids for alcoholic hepatitis--what's next? J Hepatol. 2005 Sep;43(3):526-33. Review.</citation>
    <PMID>16026887</PMID>
  </results_reference>
  <results_reference>
    <citation>Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broët P, Emilie D; Foie-Alcool group of the Association Française pour l'Etude du Foie. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004 May;39(5):1390-7.</citation>
    <PMID>15122768</PMID>
  </results_reference>
  <results_reference>
    <citation>Mathurin P, Abdelnour M, Ramond MJ, Carbonell N, Fartoux L, Serfaty L, Valla D, Poupon R, Chaput JC, Naveau S. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology. 2003 Dec;38(6):1363-9.</citation>
    <PMID>14647046</PMID>
  </results_reference>
  <results_reference>
    <citation>Mathurin P, Mendenhall CL, Carithers RL Jr, Ramond MJ, Maddrey WC, Garstide P, Rueff B, Naveau S, Chaput JC, Poynard T. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol. 2002 Apr;36(4):480-7.</citation>
    <PMID>11943418</PMID>
  </results_reference>
  <results_reference>
    <citation>Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S, Benhamou JP, Chaput JC, Rueff B, Poynard T. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology. 1996 Jun;110(6):1847-53.</citation>
    <PMID>8964410</PMID>
  </results_reference>
  <results_reference>
    <citation>Ramond MJ, Poynard T, Rueff B, Mathurin P, Théodore C, Chaput JC, Benhamou JP. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med. 1992 Feb 20;326(8):507-12.</citation>
    <PMID>1531090</PMID>
  </results_reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2010</study_first_submitted>
  <study_first_submitted_qc>October 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2010</study_first_posted>
  <last_update_submitted>May 31, 2011</last_update_submitted>
  <last_update_submitted_qc>May 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Service des Maladies de l'Appareil Digestif, Hôpital Huriez,</name_title>
    <organization>CHRU Lille, France (Pr Philippe Mathurin / MD, PhD)</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
    <mesh_term>Liver Diseases, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

